Incyte (INCY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY)

INCY 102.05

+0.3%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Peter Singleton who wrote (651)	5/29/1998 3:40:00 PM
From: Rocketman	Read Replies (1) of 3202

RESEARCH ALERT - Incyte restarted Friday May 29, 2:54 pm Eastern Time NEW YORK, May 29 (Reuters) - SBC Warburg Dillon Read said on Friday it restarted coverage on shares of Incyte Pharmaceuticals with a buy rating. -- Company has established itself as dominant player in the fast growing genomics industry, analyst A. Rachel Leheny said. -- Company has built a proprietary database that contains the majority of human genes as well as a group of related databases including a full-length clone database. -- Stock has recently been under pressure due to perceptions of competition in its midst but analyst said believes competition has been overstated. biz.yahoo.com >>>>>>>>>>> They are starting to catch on!!! Rman

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next